Consultant
Olfred Hansen
Department of Oncology, Odense University Hospital
Projekt styring | ||
Projekt status | Sampling ongoing | |
Data indsamlingsdatoer | ||
Start | 01.01.2015 | |
Slut | 31.12.2017 | |
This randomized phase III study 2-arm investigates the effect of increasing the radiation dose by definitive chemo-radiotherapy of patients with inoperable loco-regional advanced Non-Small Cell Lung Cancer (NSCLC). The radiation dose is increased to tumor and lymph nodes based on inhomogeneous dose distribution determined by the most active (FDG-PET criteria) area of the node in the experimental arm. Patients in the control arm will receive standard uniform dose distribution. In both, the treatment arms are over 33 fractions. In the experimental arm the dose is kept as high as possible, taking into consideration normal tissue tolerance. In the control arm 66 Gy.
NSCLC has very often spread to the lymph nodes between the lungs or grown into the surroundings at the time of diagnosis. Then concurrent chemo-radiation is the treatment of choice. However, survival is poor with a median survival of 20 months and a 5 year survival of 15-20% in clinical trials. Lack of loco-regional control is one of the reasons for the poor survival and improvement in the loco-regional control by increasing the radiation dose will probably lead to an improved survival. Complications in the normal tissue, especially the lungs, may be fatal and are the limiting factors. The risk of side effects is dependent on the dose to normal tissue, and the volume of normal tissue being irradiated. In this study, we try to increase the dose to the portion of the tumor most resistant to radiotherapy without increasing the volume of and dose to irradiated crucial normal tissue.
Patients with newly diagnosed locally advanced NSCLC suitable for radical chemo-radiation to a dose of 66 Gy. The patients have to be performance status 0-1, have no other active cancer, and be in general stable medical condition.
Data on patients' demographics, stage, histology, radiotherapy, volume and dose. Outcome date such as survival, local-control, toxicity.
Department of Oncology, Odense University Hospital
Laboratory of Radiation Physics, Odense University Hospital
Department of Nuclear Medicine, Odense University Hospital
Department of Oncology, Aarhus University Hospital
Department of Medial Physics, Aarhus University Hospital
Department of Nuclear Medicine, Aarhus University Hospital
Department of Oncology, Vejle Hospital
Laboratory of Radiation Physics, Vejle Hospital
Department of Nuclear Medicine, Vejle Hospital
Department of Oncology, Aalborg University Hospital
Department of Medial Physics, Aalborg University Hospital
Department of Nuclear Medicine, Aalborg University Hospital
Department of Oncology, Herlev Hospital
Department Medical Physics, Herlev Hospital
Department of Nuclear Medicine, Herlev Hospital
Clinic of Oncology, Copenhagen University Hospital, Rigshospitalet
Clinic of Radiotherapy, Copenhagen University Hospital, Rigshospitalet
Clinic for Clinical Physiology, Nuclear Medicin and PET, Copenhagen University Hospital, Rigshospitalet
Department of Oncology, Næstved Hospital
Department of Nuclear Medicine, Næstved Hospital